ATE397621T1 - Hemmer der interaktion zwischen p53 und mdm2 - Google Patents
Hemmer der interaktion zwischen p53 und mdm2Info
- Publication number
- ATE397621T1 ATE397621T1 AT97935511T AT97935511T ATE397621T1 AT E397621 T1 ATE397621 T1 AT E397621T1 AT 97935511 T AT97935511 T AT 97935511T AT 97935511 T AT97935511 T AT 97935511T AT E397621 T1 ATE397621 T1 AT E397621T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- mdm2
- interaction
- human
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Amplifiers (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9614197.3A GB9614197D0 (de) | 1996-07-05 | 1996-07-05 | |
GBGB9707041.1A GB9707041D0 (en) | 1997-04-07 | 1997-04-07 | Inhibitors of the interaction between p53 and mdm2 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE397621T1 true ATE397621T1 (de) | 2008-06-15 |
Family
ID=26309649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97935511T ATE397621T1 (de) | 1996-07-05 | 1997-07-04 | Hemmer der interaktion zwischen p53 und mdm2 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0958305B1 (de) |
JP (1) | JP2001500365A (de) |
AT (1) | ATE397621T1 (de) |
AU (1) | AU3847997A (de) |
CA (1) | CA2259149A1 (de) |
DE (1) | DE69738754D1 (de) |
NZ (1) | NZ333609A (de) |
WO (1) | WO1998001467A2 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
GB9708092D0 (en) * | 1997-04-22 | 1997-06-11 | Univ Dundee | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
AU7238098A (en) * | 1997-05-15 | 1998-12-08 | Kyowa Hakko Kogyo Co. Ltd. | Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants |
US6238921B1 (en) * | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
EP0947494A1 (de) * | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Phenoxyessigsäure- und Phenoxymethyltetrazolderivate mit Antitumoraktivität |
ATE283915T1 (de) * | 1998-05-26 | 2004-12-15 | Inst Of Molecul & Cell Biology | Polypeptide aus dem creb-bindenden protein und verwandten protein p-300 zur verwendung bei der transkriptionellen regulation |
GB9819860D0 (en) * | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US20040038902A1 (en) | 2000-04-05 | 2004-02-26 | Pincus Matthew R. | Peptides selectively lethal to malignant and transformed mammalian cells |
EP1633749A4 (de) | 2003-02-13 | 2011-03-02 | Us Gov Health & Human Serv | Deazaflavinverbindungen und verfahren zu deren anwendung |
CN107090025A (zh) | 2003-11-05 | 2017-08-25 | 达纳-法伯癌症研究所股份有限公司 | 稳定的α螺旋肽及其用途 |
WO2005097820A1 (en) * | 2004-04-06 | 2005-10-20 | Korea Research Institute Of Bioscience And Biotechnology | Peptides for inhibiting mdm2 function |
WO2005114173A2 (en) * | 2004-04-22 | 2005-12-01 | Ortho-Mcneil Pharmaceuticals, Inc. | Hdm2-inhibitor complexes and uses thereof |
JP5649825B2 (ja) | 2007-01-31 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 安定化させたp53ペプチドおよびその使用法 |
KR20160061439A (ko) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
CN102256615A (zh) | 2009-01-14 | 2011-11-23 | 爱勒让治疗公司 | 拟肽大环化合物 |
EP2444105A4 (de) * | 2009-06-16 | 2013-08-21 | Univ Tokai | Anti-gram-negativer bakterieller wirkstoff |
WO2011005219A1 (en) * | 2009-07-07 | 2011-01-13 | Agency For Science, Technology And Research | Novel mdm2 binding peptides and uses thereof |
EA201200321A1 (ru) | 2009-08-26 | 2012-09-28 | Новартис Аг | Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4 |
CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
KR20140100937A (ko) | 2011-10-18 | 2014-08-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
CN103974973A (zh) * | 2011-11-09 | 2014-08-06 | 莫茨制药有限及两合公司 | 显示出缩短的生物学活性的神经毒素 |
US9408885B2 (en) * | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
CN107216380A (zh) | 2012-02-15 | 2017-09-29 | 爱勒让治疗公司 | 拟肽大环化合物 |
CN104144695A (zh) | 2012-02-15 | 2014-11-12 | 爱勒让治疗公司 | ***交联的和硫醚交联的拟肽大环化合物 |
EP2855483B1 (de) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinonverbindungen |
KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
EP2948453B1 (de) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinonverbindungen als inhibitoren der p53/mdm2-interaktion |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
EP3004109A1 (de) | 2013-05-27 | 2016-04-13 | Novartis AG | Imidazopyrrolidinonderivate und deren verwendung bei der behandlung einer krankheit |
US9714249B2 (en) | 2013-05-28 | 2017-07-25 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
US9624247B2 (en) | 2013-05-28 | 2017-04-18 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
JP2016537384A (ja) | 2013-11-21 | 2016-12-01 | ノバルティス アーゲー | ピロロピロロン誘導体およびbet阻害剤としてのその使用 |
SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
EP3294318A4 (de) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | Peptidomimetische makrozyklen und verwendungen davon |
US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
WO2017044633A1 (en) | 2015-09-10 | 2017-03-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of mcl-1 |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
EP3724216A1 (de) | 2017-12-15 | 2020-10-21 | Dana Farber Cancer Institute, Inc. | Durch stabilisiertes peptid vermittelter zielgerichteter proteinabbau |
US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
CN109206474A (zh) * | 2018-11-27 | 2019-01-15 | 青岛海洋生物医药研究院 | 一种线性肽合成方法 |
US20220153868A1 (en) * | 2019-02-20 | 2022-05-19 | Oncolyze, Inc | Hdm2 antibody for use in treating cancer |
CN112266407B (zh) * | 2020-09-28 | 2023-05-12 | 宁夏医科大学总医院 | 特异结合p53蛋白的七肽、编码基因、制备方法及用途 |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
-
1997
- 1997-07-04 WO PCT/EP1997/003549 patent/WO1998001467A2/en active IP Right Grant
- 1997-07-04 EP EP97935511A patent/EP0958305B1/de not_active Expired - Lifetime
- 1997-07-04 CA CA002259149A patent/CA2259149A1/en not_active Abandoned
- 1997-07-04 DE DE69738754T patent/DE69738754D1/de not_active Expired - Fee Related
- 1997-07-04 AT AT97935511T patent/ATE397621T1/de not_active IP Right Cessation
- 1997-07-04 AU AU38479/97A patent/AU3847997A/en not_active Abandoned
- 1997-07-04 JP JP10504775A patent/JP2001500365A/ja not_active Withdrawn
- 1997-07-04 NZ NZ333609A patent/NZ333609A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU3847997A (en) | 1998-02-02 |
EP0958305B1 (de) | 2008-06-04 |
JP2001500365A (ja) | 2001-01-16 |
NZ333609A (en) | 2000-08-25 |
EP0958305A2 (de) | 1999-11-24 |
DE69738754D1 (de) | 2008-07-17 |
CA2259149A1 (en) | 1998-01-15 |
WO1998001467A2 (en) | 1998-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE397621T1 (de) | Hemmer der interaktion zwischen p53 und mdm2 | |
GEP20043363B (en) | Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation | |
EA200000723A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
ES2157994T3 (es) | Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa. | |
AU3804500A (en) | 2-amino-6-anilino-purines and their use as medicaments | |
MXPA02011303A (es) | Nueva composicion farmaceutica. | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
ATE284959T1 (de) | Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung | |
WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
UA66865C2 (uk) | Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти) | |
DE69426334D1 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
IL153680A0 (en) | Aplidine derivatives and methods for the preparation thereof | |
RU95111308A (ru) | Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция | |
EA200500934A1 (ru) | Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний | |
WO2001018046A3 (en) | Ovarian tumor sequences and methods of use therefor | |
HUT64569A (en) | A process for preparing polypeptide-type compounds usefules for medical treatment of the human body | |
IL143516A0 (en) | COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B | |
ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0958305 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |